TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 117 filers reported holding TARSUS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,074 | -25.2% | 39,499 | +0.1% | 0.00% | -50.0% |
| Q1 2024 | $1,435 | +167.2% | 39,479 | +48.9% | 0.00% | +100.0% |
| Q4 2023 | $537 | +13.8% | 26,518 | -0.2% | 0.00% | 0.0% |
| Q3 2023 | $472 | +140.8% | 26,566 | +145.0% | 0.00% | – |
| Q2 2023 | $196 | +20.2% | 10,842 | -16.4% | 0.00% | – |
| Q1 2023 | $163 | -14.2% | 12,965 | 0.0% | 0.00% | – |
| Q4 2022 | $190 | -99.9% | 12,965 | +0.1% | 0.00% | – |
| Q3 2022 | $222,000 | +18.1% | 12,948 | +0.7% | 0.00% | – |
| Q2 2022 | $188,000 | +89.9% | 12,860 | +118.7% | 0.00% | – |
| Q1 2022 | $99,000 | -25.0% | 5,881 | +0.2% | 0.00% | – |
| Q4 2021 | $132,000 | +3.9% | 5,872 | -0.2% | 0.00% | – |
| Q3 2021 | $127,000 | -53.1% | 5,881 | -37.1% | 0.00% | – |
| Q2 2021 | $271,000 | +42.6% | 9,353 | +58.5% | 0.00% | – |
| Q1 2021 | $190,000 | +31.0% | 5,900 | +68.6% | 0.00% | – |
| Q4 2020 | $145,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,254,797 | $61,285,382 | 6.24% |
| Ikarian Capital, LLC | 800,277 | $21,751,529 | 3.79% |
| TFG Asset Management GP Ltd | 500,000 | $13,590,000 | 3.39% |
| Paradigm Biocapital Advisors LP | 2,435,416 | $66,194,607 | 2.53% |
| Frazier Life Sciences Management, L.P. | 1,587,527 | $43,148,984 | 2.02% |
| Ghost Tree Capital, LLC | 235,000 | $6,387,300 | 2.00% |
| COWEN AND COMPANY, LLC | 2,197,385 | $59,724,924 | 1.64% |
| TCG Crossover Management, LLC | 556,317 | $15,120,696 | 1.58% |
| Sands Capital Ventures, LLC | 170,000 | $4,620,600 | 1.55% |
| BOONE CAPITAL MANAGEMENT LLC | 216,047 | $5,872,157 | 1.53% |